Adalimumab after surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You had surgery to remove all visible cancer (R0 resection) 4 to 16 weeks ago
- Your cancer is a specific type called esophageal squamous cell carcinoma and was at certain stages before surgery
- You are in good general health with no major organ problems
- You have no active autoimmune diseases or hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether giving an immunotherapy drug called adebrelimab (with other drugs) before surgery can help shrink the tumor and improve outcomes for people with a certain type of esophageal cancer. The goal is to make surgery more effective and potentially reduce the chance of cancer coming back.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
Hear when a new Squamous Oesophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.